| Description |
Indibulin (ZIO 301) , an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis[1].
|
| In Vitro |
Indibulin (300-2100 nM; 48 hours) inhibits the proliferation of MCF-7 cells with an IC50 of 150 nM[1]. Indibulin (300, 600 nM; 48 hours) blockes the cells in the G2/M phase indicating that indibulin blockes the progression of the cell cycle at mitosis[1]. Indibulin (150-600 nM; 24 hours) induces apoptosis in MCF-7 cells[1]. Indibulin (150-600 nM; 48 hours) with 300 and 600 nM generates cleaved fragments of PARP protein the treatment of MCF-7 cells[1]. Cell Proliferation Assay[1] Cell Line: MCF-7 cells Concentration: 300, 600, 900, 1200, 1500, 1800, 2100 nM Incubation Time: 48 hours Result: Inhibited the proliferation of MCF-7 cells with an IC50 of 150 nM. Cell Cycle Analysis[1] Cell Line: MCF-7 cells Concentration: 300, 600 nM Incubation Time: 48 hours Result: Blocked the cells in the G2/M phase of the cell cycle. Apoptosis Analysis[1] Cell Line: MCF-7 cells Concentration: 150, 300 and 600 nM Incubation Time: 24 hours Result: Induced apoptosis in MCF-7 cells. Western Blot Analysis[1] Cell Line: MCF-7 cells Concentration: 150, 300 and 600 nM Incubation Time: 48 hours Result: Generated cleaved fragments of PARP protein in 300 and 600 nM.
|
